DOCSLIB.ORG

Development of Novel Antibacterial Agents Through the Design and Synthesis of Aminoacyl Trna Synthetase (Aars) Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Medicinal Chemistry Division, Cardiff school of Pharmacy and Pharmaceutical Sciences, Cardiff University Development of Novel Antibacterial Agents through the Design and Synthesis of Aminoacyl tRNA Synthetase (AaRS) Inhibitors A thesis submitted in accordance with the conditions governing candidates for the degree of Philosophiae Doctor in Cardiff University Hanadi Asiri Supervisors: Dr. Claire Simons Dr. Efi Mantzourani December 2020 Acknowledgements Thanks God Almighty for good health, peace of mind and the strength to finish this research despite the difficult situations. Thanks God, for giving me chance to know Dr. Claire Simons. I would like to express my sincere gratitude to my supervisor Dr. Claire Simons for her continuous support, guidance, teaching, patience, enthusiasm and endless helping throughout my PhD journey. The completion of this thesis could not have been possible without her valuable experience. I would like to thank Dr. Efi Mantzourani for her support and valuable advice throughout the course of this research. Thanks to the EPSRC mass spectrometry service centre, Shaun Reeksting from Bath University and Medac Ltd. for the accurate mass, HPLC measurements and the microanalysis determination. A Big thank to Jennifer Richard, Dr. Mandy Wootton, Casey Hughes and Dr. James Bullard for the antimicrobial screening test and aminoacylation assay results. Finally, many thanks to all the members in Cardiff University who help and encourage me and do not forget to thank my mum (Aminah Al-Anbar), sisters (Al-Anoud and Alaa Asiri), brother (Abdullah Asiri), children (Amal, Yaser, Yazen and Nouf) and my husband (Musaad Al-Makhilib) for their unconditional support, love and encouragement. iii In the name of God, most gracious, most Merciful This thesis is dedicated to my supervisor (Claire Simons) for her support Read! In the Name of your Lord who has created ❶ He has created man from a clot ❷ Read! And your Lord is the most Generous ❸ Who has taught (the writing) by the pen ❹ He has taught man that which he knew not ❺ Nay! Verily, man does transgress (in disbelief and evil deed) ❻ Because he considers himself self-sufficient ❼ Surely, to your Lord is the return❽ Surah Al-Alag (The Clot) (96) iv Abstract Antimicrobial resistance is a global public health issue which significantly threatens human life. There are approximately 50,000 deaths in the USA and Europe per year owing to antimicrobial resistance infections. This burden of resistance has increased resulting in an increase in morbidity and mortality in clinical and community setting. Thus, global collaborative action is needed for developing effective strategies to combat antimicrobial resistance. International and local approaches including antimicrobial surveillance, guidelines for treatment of bacterial infections, regulation of the availability of antibiotics, improving hand hygiene, understanding the mechanism of bacterial resistance and development of new antimicrobial agents have been advised. Aminoacyl tRNA synthetases are valuable targets for antibiotic development as they have a fundamental role at a cellular level during the translation process of the genetic code. Mupirocin (Bactroban ®) is an approved isoleucine tRNA synthetase inhibitor which is used for the treatment of methicillin resistant Staphylococcus aureus (MRSA). High and low level of mupirocin resistance has been demonstrated in most S. aureus isolates due to acquired plasmid-mediated mupA, which encodes a novel IleRS and mutation, respectively. Thus, the design of multitarget aminoacyl tRNA synthetases inhibitors could be an effective way to make significant reductions in the biological fitness of bacteria leading to a reduction in drug resistant microorganisms. Class IIb aminoacyl tRNA synthetases of which AspRS and AsnRS belong is a target of the project in Staphylococcus aureus and Enterococcus faecalis. A computational study of both enzymes in both microorganisms including homology modelling, validation techniques, molecular dynamics and docking of the natural substrates (aa-AMP) were used to be a platform for the design of dual site inhibitors containing a sulphamoyl linkage which mimic aa-AMP in both enzymes. Different series of AspRS/AsnRS inhibitors were designed to occupy both pockets of the target enzymes then synthesised after optimisation their synthetic routes. The minimum inhibitory concentration of compounds against a panel of microorganisms were evaluated compared with ciprofloxacin as the standard and one compound showed good inhibitory activity against Enterococcus faecalis (MIC = 2 µg/mL). v Content Content No. Chapter 1 1 1. Introduction 2 1.1. Antimicrobial resistance (AMR) 2 1.2. Mechanism of bacterial resistance 4 1.3. Gram positive bacteria 8 1.3.1. Staphylococcus aureus 9 1.3.1.1. Structure of Staphylococcus aureus 9 1.3.1.2. Methicillin resistant Staphylococcus aureus (MRSA) 10 1.3.1.3. Diseases related to Staphylococcus aureus 11 1.3.1.3.1. Staphylococcus aureus bacteraemia (SAB) 11 1.3.1.3.2. Infective endocarditis 12 1.3.1.3.3. Pleuropulmonary infection 12 1.3.1.3.4. Skin and soft tissue infection 12 1.3.1.3.5. Osteoarticular infection 13 1.3.2. Enterococcus faecalis 14 1.3.2.1. Resistance in Enterococcus faecalis 14 1.4. Aminoacyl tRNA synthetases 15 1.4.1. Classification of aminoacyl tRNA synthetases 17 1.4.2. Aminoacylation proofreading 24 1.4.3. Indirect pathway of aminoacylation 25 1.4.4. Other functions of aminoacyl tRNA synthetases 25 1.4.5. Aminoacyl tRNA synthetases inhibitors 27 1.5. Aim and objectives 36 Chapter 2 37 2. Introduction 38 2.1. Staphylococcus aureus aminoacyl tRNA synthetases 41 2.1.1. Class I S. aureus aminoacyl tRNA synthetases 41 2.1.2. Class II S. aureus aminoacyl tRNA synthetases 42 2.2. Enterococcus faecalis aminoacyl tRNA synthetases 46 2.2.1. Class I E. faecalis aminoacyl tRNA synthetases 46 2.2.2. Class II E. faecalis aminoacyl tRNA synthetases 47 2.3. Result and discussion 51 2.3.1. Computational analysis of S. aureus aminoacyl tRNA synthetases 51 2.3.1.1. Construction of S. aureus AspRS and AsnRS models 52 2.3.1.1.1. Homology search of S. aureus AspRS and AsnRS 52 2.3.1.2. Multiple sequence and structure alignment 56 2.3.1.3. 3D S. aureus AspRS and AsnRS models building and validation 60 2.3.1.4. Docking study of S. aureus AspRS and AsnRS models 72 2.3.1.4.1. Active site identification 72 2.3.1.4.2. Metal binding 78 2.3.1.5. Molecular dynamic of S. aureus AspRS and AsnRS models 81 2.3.1.6. Final constructed S. aureus AspRS and AsnRS models 85 2.3.2. Computational analysis of E. faecalis aminoacyl tRNA synthetases 88 2.3.2.1. Construction of E. faecalis AspRS and AsnRS models 89 2.3.2.1.1. Homology search of E. faecalis AspRS and AsnRS 89 vi 2.3.2.1.2. Multiple sequence and structure alignment 93 2.3.2.1.3. 3D E. faecalis AspRS and AsnRS models building and validation 97 2.3.2.1.4. Docking study of E. faecalis AspRS and AsnRS models 109 2.3.2.1.4.1. Active site identification 109 2.3.2.1.4.2. Metal binding 114 2.3.2.1.5. Molecular dynamic of E. faecalis AspRS and AsnRS models 117 2.2.2.1.6. Final constructed E. faecalis AspRS and AsnRS models 121 2.4. Selectivity study of S. aureus and E. faecalis AspRS and AsnRS with their 123 human counterparts 2.5. Methods 126 2.5.1. Homology search 126 2.5.2. Multiple sequence and structure alignment 126 2.5.3. 3D model building 127 2.5.4. Model validation 127 2.5.5. Docking study 128 2.5.6. Molecular dynamic 128 2.5.7. Binding affinity (ΔG) calculations 128 Chapter 3 130 3. Introduction 131 3.1. Synthetic pathway for sulphonyl piperazinyl methanone derivatives 133 (7, 10 and 14) 3.1.1. Synthesis of sulfonyl piperazine derivatives (3a-f) 136 3.1.2. Synthesis of acid chlorides (6 and 9) 138 3.1.3. Synthesis of sulfonyl piperazinyl methanone derivatives (7a-f, 10a-d 139 and 14a-d) 3.2. Docking studies 142 3.2.1. Docking studies of S. aureus AspRS 142 3.2.2. Docking studies of S. aureus AsnRS 148 3.2.3. Docking studies of E. faecalis AspRS 154 3.2.4. Docking studies of E. faecalis AsnRS 159 3.3. Molecular dynamic studies 165 3.4. Biological assays 169 3.4.1. Microbiological screening 169 3.4.2. Aminoacylation assay 175 3.5. Methods 178 3.5.1. Docking and molecular dynamic studies 178 3.5.2. Biological assay 178 3.5.2.1. Antimicrobial screening test 178 3.5.2.2. Aminoacylation assay 179 3.5.3. Chemistry 179 3.5.3.1. General procedure for the preparation of phenyl sulfonyl 180 piperazines (3a-f) (329) 3.5.3.1.1. 1-Tosyl piperazine (3a) 181 3.5.3.1.2. 1-((4-Nitrophenyl)sulfonyl)piperazine (3b) 181 3.5.3.1.3. 1-([1,1'-Biphenyl]-4-yl)sulfonyl)piperazine (3c) 181 3.5.3.1.4. 1-((4’-Methoxy-[1,1’-biphenyl]-4-yl)sulfonyl)piperazine (3d) 181 3.5.3.1.5. 1-((4'-Fluoro-[1,1'-biphenyl]-4-yl)sulfonyl)piperazine (3e) 182 vii 3.5.3.1.6. 1-((4'-Chloro-[1,1'-biphenyl]-4-yl)sulfonyl)piperazine (3f) 182 3.5.3.2. General procedure for the preparation of acid chlorides (6 and 9) 182 3.5.3.2.1. 5-Methylisoxazole-4-carbonyl chloride (6) 183 3.5.3.2.2. 4-Methylthiazole-5-carbonyl chloride (9) 183 3.5.3.3. General procedure for the preparation of (5-methylisoxazol-4-yl)(4- 183 ((4-phenyl)sulfonyl)piperazin-1-yl)methanone derivatives (7a-f) and (4- methylthiazol-5-yl)(4-((4-phenyl)sulfonyl)piperazin-1-yl)methanone derivatives (10a-d).
Recommended publications
  • Genetically Modified Baculoviruses for Pest

    Genetically Modified Baculoviruses for Pest

    INSECT CONTROL BIOLOGICAL AND SYNTHETIC AGENTS This page intentionally left blank INSECT CONTROL BIOLOGICAL AND SYNTHETIC AGENTS EDITED BY LAWRENCE I. GILBERT SARJEET S. GILL Amsterdam • Boston • Heidelberg • London • New York • Oxford Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo Academic Press is an imprint of Elsevier Academic Press, 32 Jamestown Road, London, NW1 7BU, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA ª 2010 Elsevier B.V. All rights reserved The chapters first appeared in Comprehensive Molecular Insect Science, edited by Lawrence I. Gilbert, Kostas Iatrou, and Sarjeet S. Gill (Elsevier, B.V. 2005). All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publishers. Permissions may be sought directly from Elsevier’s Rights Department in Oxford, UK: phone (þ44) 1865 843830, fax (þ44) 1865 853333, e-mail [email protected]. Requests may also be completed on-line via the homepage (http://www.elsevier.com/locate/permissions). Library of Congress Cataloging-in-Publication Data Insect control : biological and synthetic agents / editors-in-chief: Lawrence I. Gilbert, Sarjeet S. Gill. – 1st ed. p. cm. Includes bibliographical references and index. ISBN 978-0-12-381449-4 (alk. paper) 1. Insect pests–Control. 2. Insecticides. I. Gilbert, Lawrence I. (Lawrence Irwin), 1929- II. Gill, Sarjeet S. SB931.I42 2010 632’.7–dc22 2010010547 A catalogue record for this book is available from the British Library ISBN 978-0-12-381449-4 Cover Images: (Top Left) Important pest insect targeted by neonicotinoid insecticides: Sweet-potato whitefly, Bemisia tabaci; (Top Right) Control (bottom) and tebufenozide intoxicated by ingestion (top) larvae of the white tussock moth, from Chapter 4; (Bottom) Mode of action of Cry1A toxins, from Addendum A7.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Can PDE Inhibition Improve Cognition? : Translational Insights

    Can PDE Inhibition Improve Cognition? : Translational Insights

    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
  • Discovery, Synthesis and Structure-Activity Relationship Study

    Discovery, Synthesis and Structure-Activity Relationship Study

    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 12-18-2020 Antiparasitic Peptide from the Ocean: Discovery, Synthesis and Structure-Activity Relationship Study Kh Tanvir Ahmed Follow this and additional works at: https://dsc.duq.edu/etd Part of the Medicinal Chemistry and Pharmaceutics Commons Recommended Citation Ahmed, K. (2020). Antiparasitic Peptide from the Ocean: Discovery, Synthesis and Structure-Activity Relationship Study (Master's thesis, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1924 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. ANTIPARASITIC PEPTIDE FROM THE OCEAN: DISCOVERY, SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP STUDY A Thesis Submitted to the Graduate School of Pharmaceutical Sciences Duquesne University In partial fulfillment of the requirements for the degree of Master of Science By Kh Tanvir Ahmed December 2020 Copyright by Kh Tanvir Ahmed 2020 ANTIPARASITIC PEPTIDE FROM THE OCEAN: DISCOVERY, SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP STUDY By Kh Tanvir Ahmed Approved August 21, 2020 ________________________________ ________________________________ Kevin J. Tidgewell, Ph.D. Aleem Gangjee, Ph.D. Associate Professor of Medicinal Professor of Medicinal Chemistry Chemistry (Committee Member) (Committee Chair) ________________________________ ________________________________
  • Downloaded, Instead, and Converted to 3D Using Obabel (O’Boyle Et Al., 2011)

    Downloaded, Instead, and Converted to 3D Using Obabel (O’Boyle Et Al., 2011)

    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.225821; this version posted July 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 New tyrosinases with a broad spectrum of action against contaminants of emerging 2 concern: Insights from in silico analyses 3 4 Marcus V. X. Senra† & Ana Lúcia Fonseca 5 6 Instituto de Recursos Naturais, Universidade Federal de Itajubá, 37500-903, Itajubá, Minas 7 Gerais – Brazil 8 †Corresponding author – [email protected]; Orcid - 0000-0002-3866-8837 9 10 Abstract 11 Tyrosinases (EC 1.14.18.1) are type-3 copper metalloenzymes with strong oxidative capacities 12 and low allosteric selectivity to phenolic and non-phenolic aromatic compounds that have been 13 used as biosensors and biocatalysts to mitigate the impacts of environmental contaminants over 14 aquatic ecosystems. However, the widespread use of these polyphenol oxidases is limited by 15 elevated production costs and restricted knowledge on their spectrum of action. Here, six 16 tyrosinase homologs were identified and characterized from the genomes of 4 widespread 17 freshwater ciliates using bioinformatics. Binding energies between 3D models of these 18 homologs and ~1000 contaminants of emerging concern (CECs), including fine chemicals, 19 pharmaceuticals, personal care products, illicit drugs, natural toxins, and pesticides were 20 estimated through virtual screening, suggesting their spectrum of action and potential uses in 21 environmental biotechnology might be considerably broader than previously thought.
  • Recent Molecular Enhancement Influenced by Natural Nootropic

    Recent Molecular Enhancement Influenced by Natural Nootropic

    Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 4391375, 12 pages http://dx.doi.org/10.1155/2016/4391375 Review Article Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic Noor Azuin Suliman,1 Che Norma Mat Taib,1 Mohamad Aris Mohd Moklas,1 Mohd Ilham Adenan,2 Mohamad Taufik Hidayat Baharuldin,1 and Rusliza Basir1 1 DepartmentofHumanAnatomy,FacultyofMedicineandHealthSciences,UniversitiPutraMalaysia,43400Serdang,Malaysia 2Atta-ur-Rahman Institute for Natural Product Discovery, Aras 9 Bangunan FF3, UiTM Puncak Alam, Bandar Baru Puncak Alam, 42300 Selangor Darul Ehsan, Malaysia Correspondence should be addressed to Che Norma Mat Taib; [email protected] Received 31 May 2016; Accepted 18 July 2016 Academic Editor: Manel Santafe Copyright © 2016 Noor Azuin Suliman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nootropics or smart drugs are well-known compounds or supplements that enhance the cognitive performance. They work by increasing the mental function such as memory, creativity, motivation, and attention. Recent researches were focused on establishing a new potential nootropic derived from synthetic and natural products. The influence of nootropic in the brain has been studied widely. The nootropic affects the brain performances through number of mechanisms or pathways, for example, dopaminergic pathway. Previous researches have reported the influence of nootropics on treating memory disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Those disorders are observed to impair the same pathways of the nootropics.
  • The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
  • (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee Et Al

    (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee Et Al

    US00779531 OB2 (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee et al. (45) Date of Patent: Sep. 14, 2010 (54) METHODS AND REAGENTS FOR THE WO WO 2005/025673 3, 2005 TREATMENT OF METABOLIC DISORDERS OTHER PUBLICATIONS (75) Inventors: Margaret S. Lee, Middleton, MA (US); Tenenbaum et al., “Peroxisome Proliferator-Activated Receptor Grant R. Zimmermann, Somerville, Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in MA (US); Alyce L. Finelli, Patients With Coronary Artery Disease'. Circulation, 2004, pp. 2197 Framingham, MA (US); Daniel Grau, 22O2.* Shen et al., “Effect of gemfibrozil treatment in sulfonylurea-treated Cambridge, MA (US); Curtis Keith, patients with noninsulin-dependent diabetes mellitus'. The Journal Boston, MA (US); M. James Nichols, of Clinical Endocrinology & Metabolism, vol. 73, pp. 503-510, Boston, MA (US) 1991 (see enclosed abstract).* International Search Report from PCT/US2005/023030, mailed Dec. (73) Assignee: CombinatoRx, Inc., Cambridge, MA 1, 2005. (US) Lin et al., “Effect of Experimental Diabetes on Elimination Kinetics of Diflunisal in Rats.” Drug Metab. Dispos. 17:147-152 (1989). (*) Notice: Subject to any disclaimer, the term of this Abstract only. patent is extended or adjusted under 35 Neogi et al., “Synthesis and Structure-Activity Relationship Studies U.S.C. 154(b) by 0 days. of Cinnamic Acid-Based Novel Thiazolidinedione Antihyperglycemic Agents.” Bioorg. Med. Chem. 11:4059-4067 (21) Appl. No.: 11/171,566 (2003). Vessby et al., “Effects of Bezafibrate on the Serum Lipoprotein Lipid and Apollipoprotein Composition, Lipoprotein Triglyceride Removal (22) Filed: Jun. 30, 2005 Capacity and the Fatty Acid Composition of the Plasma Lipid Esters.” Atherosclerosis 37:257-269 (1980).
  • Design and Study of Piracetam-Like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs

    Design and Study of Piracetam-Like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs

    Current Pharmaceutical Design, 2002, 8, 125-138 125 Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs Fulvio Gualtieri°*, Dina Manetti°, Maria Novella Romanelli° and Carla Ghelardini^ °Dipartimento di Scienze Farmaceutiche, Universita' di Firenze, Via G. Capponi 9, I-50121 Firenze, Italy ^Dipartimento di Farmacologia Preclinica e Clinica, Universita' di Firenze, Viale Pieraccini 6, I-50139 Firenze, Italy Abstract- Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and age-related pathologies. Development of cognition enhancers is still a difficult task because of complexity of the brain functions, poor predictivity of animal tests and lengthy and expensive clinical trials. After the early serendipitous discovery of first generation cognition enhancers, current research is based on a variety of working hypotheses, derived from the progress of knowledge in the neurobiopathology of cognitive processes. Among other classes of drugs, piracetam-like cognition enhancers (nootropics) have never reached general acceptance, in spite of their excellent tolerability and safety. In the present review, after a general discussion of the problems connected with the design and development of cognition enhancers, the class is examined in more detail. Reasons for the problems encountered by nootropics, compounds therapeutically available and those in development, their structure activity relationships and mechanisms of action are discussed. Recent developments which hopefully will lead to a revival of the class are reviewed. INTRODUCTION [3]. An extremely complicated neuronal network in the brain regulates the complex mechanism of learning and memory.
  • The Calcium/Calmodulin-Dependent Kinases II and IV As Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders

    The Calcium/Calmodulin-Dependent Kinases II and IV As Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders

    International Journal of Molecular Sciences Review The Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders Kinga Sałaciak 1, Aleksandra Koszałka 1, Elzbieta˙ Zmudzka˙ 2 and Karolina Pytka 1,* 1 Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland; [email protected] (K.S.); [email protected] (A.K.) 2 Department of Social Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland; [email protected] * Correspondence: [email protected] Abstract: CaMKII and CaMKIV are calcium/calmodulin-dependent kinases playing a rudimentary role in many regulatory processes in the organism. These kinases attract increasing interest due to their involvement primarily in memory and plasticity and various cellular functions. Although CaMKII and CaMKIV are mostly recognized as the important cogs in a memory machine, little is known about their effect on mood and role in neuropsychiatric diseases etiology. Here, we aimed to review the structure and functions of CaMKII and CaMKIV, as well as how these kinases modulate the animals’ behavior to promote antidepressant-like, anxiolytic-like, and procognitive effects. The review will help in the understanding of the roles of the above kinases in the selected neurodegenerative and neuropsychiatric disorders, and this knowledge can be used in future drug design. Citation: Sałaciak, K.; Koszałka, A.; Zmudzka,˙ E.; Pytka, K. The Keywords: CaMKII; CaMKIV; memory; depression; anxiety; animal studies Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders. Int. J. 1.
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol

    (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol

    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
  • 9BT2018-MTI30.Pdf

    9BT2018-MTI30.Pdf

    UNIDAD ACADÉMICA DE CIENCIAS DE LA SALUD Y BIENESTAR CARRERA DE MEDICINA TRABAJO DE GRADUACIÓN PREVIO A LA OBTENCIÓN DEL TÍTULO DE MÉDICO: “PREVALENCIA Y FACTORES ASOCIADOS AL CONSUMO DE MODAFINILO, DEXTROANFETAMINA Y METILFENIDATO EN ESTUDIANTES DE LAS FACULTADES DE MEDICINA DE LA CIUDAD DE CUENCA - 2018” AUTOR: MARIO FERNANDO FÁREZ BUENAÑO DIRECTOR: DRA. ROSA ELIZABETH SOLORZANO BERNITA ASESOR: LIC. CAREM FRANCELYS PRIETO FUENMAYOR CUENCA – ECUADOR 2018 Mario Fernando Fárez Buenaño 1 RESUMEN: Antecedentes: Desde 1960 se ha documentado el consumo de medicamentos psicoestimulantes, mismo que se ha incrementado últimamente. Por adolescentes y adultos jóvenes, especialmente estudiantes de nivel superior que utilizan estas sustancias con fines recreativos o para mejorar su desempeño académico. Objetivo: Determinar la prevalencia y factores asociados al consumo de Modafinilo, Metilfenidato y Dextroanfetamina en estudiantes de las Facultades de Medicina de las Universidades de la Ciudad de Cuenca - 2018. Materiales y Métodos: Estudio observacional analítico de cohorte transversal que abarcó 418 estudiantes de 18 – 25 años de las Facultades de Medicina de las Universidades de la ciudad de Cuenca -2018. Para el análisis se utilizó el programa IBM SPSS v. 24. La asociación estadística fue considerada con un índice de confiabilidad del 95%, con un valor estadístico de p<0.05. Resultados: La prevalencia del consumo corresponde al 3.88%, el fármaco más consumido es modafinilo 26.8%. Los factores asociados son: grupo étnico blanco OR: 3.64 (IC: 1.73-7.63, p: 0.00), o negro OR: 4.51 (IC: 1.14-17.73, p: 0.01), edad comprendida entre 22 – 25 años OR: 1.68 (IC: 1.10-2.57, p: 0.01), nivel socioeconómico alto OR:1.58 (IC: 1.01-2.49, p: 0.04), consumo de alcohol OR: 1.98 (IC: 1.00-3.90, p: 0.04), consumo de cannabis 4.54 (IC: 2.82-7.30, p: 0.00), tener amigos que consuman estos fármacos OR: 7.12 (IC: 4.34-11.68, p: 0.00).